Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Cerebral Amyloid Angiopathy in AD

Defining cognitive associations

Publish date:: November 11, 2015

Cerebral amyloid angiopathy (CAA) is an important determinant of Alzheimer disease (AD) dementia and decline in multiple cognitive systems in old age, according to a study of 1,113 participants in 2 clinical-pathologic studies of aging. Researchers found:

• CAA occurred in 78.9% of participants, and was moderately related to AD pathology.

• After adjustment for plaques, tangles, and other common age-related neuropathologies, CAA was associated with increased odds of AD dementia (OR, 1.237) and increased rate of decline in global cognition, perceptual speed, episodic memory, and semantic memory.

• CAA associations with cognitive outcomes were not driven by the presence of capillary involvement.

Citation: Boyle PA, Yu L, Nag S, et al. Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. [Published online ahead of print November 4, 2015]. Neurology. doi: 10.1212/WNL.0000000000002175.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Alzheimer's & Cognition

Mortality burden of dementia may be greater than estimated,

Cognitive deficits complex in youths with type 2 diabetes,

Population study supports migraine-dementia link,

Mixed results for aducanumab in two phase 3 trials for Alzheimer’s disease,

Blood pressure lowering lessens risk of dementia, cognitive decline,